Bristol Myers Squibb stock gains 0.1 percent as earnings beat estimates

Published on 09/23/2026 at 12:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock closed at USD 62.68 on September 22, 2026, while quarterly EPS reached USD 2.04. Revenue rose 5.7 percent year over year.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) closed at USD 62.68 on the NYSE on September 22, 2026, up 0.1 percent, as the latest quarterly figures continued to exceed consensus estimates. The result gives the stock a concrete earnings anchor while the price remains USD 5.96 below its 52-week high of USD 68.64.

Quarterly earnings beat estimates

According to MarketBeat on September 22, 2026, Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.97 billion, up 5.7 percent from the same period a year earlier. Non-GAAP earnings per share reached USD 2.04, exceeding the USD 1.60 consensus estimate by USD 0.44.

The comparison is also visible against the prior-year quarter, when EPS stood at USD 1.46. The latest quarter therefore combined a USD 0.58 year-over-year increase in adjusted EPS with revenue growth, although the market response through September 22 remained limited to a USD 0.06 gain.

Guidance and pipeline costs matter

MarketBeat reported that the company set fiscal year 2026 adjusted EPS guidance at USD 6.75 to USD 7.00. Analysts cited in the same report expect fiscal-year EPS of USD 6.95, placing the consensus inside the company range rather than above it.

A counter-factor comes from operating investment. Fierce Pharma reported on September 22, 2026, that Bristol Myers Squibb increased its projection for full-year 2026 operating expenses to about USD 16.5 billion, citing prelaunch activity and development programs. That cost outlook is important because the second-quarter EPS beat included lower specified charges and the absence of a prior-year acquired in-process research and development charge.

Stock remains below yearly high

On September 22, 2026, the NYSE close of USD 62.68 stood between the 52-week low of USD 42.52 and the high of USD 68.64. The share price was USD 20.16 above the low and USD 5.96 below the high, while reported volume was 2,184,600 shares.

The valuation backdrop in the September 22 market data included a market capitalization of USD 128.04 billion and a price-to-earnings ratio of 13.80. For investors, the central numerical tension is clear: quarterly revenue grew 5.7 percent year over year and EPS beat consensus by USD 0.44, but the stock still traded below its yearly peak as the company funds future launches.